

Patient Information: Name: _____ DOB: _____ Gender: M F
 Address: _____ City: _____ State: _____ Zip: _____ Phone: _____ Alt. Phone: _____
 Email: _____ Ht: _____ Wt: _____ Care Giver: _____ Allergies: No Known See Attached Charts
Prescriber Information: Name: _____ Address: _____ City: _____
 State: _____ Zip: _____ NPI: _____ Phone: _____ Fax: _____ Office Contact: _____

Statement of Medical Necessity (Please Attach All Medical Documentation)

Date of Diagnosis: _____ **ICD-10:** _____ **Other:** _____ **TB Test:** Positive Negative **Date:** _____
LFT: ALT: _____ AST: _____ **Date:** _____ **Assessment:** Moderate Mod to Severe Severe _____% **BSA Affected**
 Scalp Face Chest Arms Hands Nails Back Groin Buttocks Legs Other _____ **ISGA or EASI** _____

Patient also taking methotrexate? Yes No
Serious or active infection present? Yes No
Hep B ruled out or treatment started? Yes No
Does patient have latex allergy? Yes No
Injection Training: Pharmacist to Provide Training
 Patient Trained in MD Office
 Manufacturer Nurse Support
 To Be Administered By a HCP
Product Delivery: Patient's Home
 Physician's Office Pharmacy to Coordinate

Prior Failed Treatments	Drug Name	Length of Treatment
<input type="radio"/> 5-ASA		
<input type="radio"/> Biologics		
<input type="radio"/> Corticosteroids		
<input type="radio"/> Immunosuppressants		
<input type="radio"/> Methotrexate		
<input type="radio"/> NSAIDS		
<input type="radio"/> Surgery		
<input type="radio"/> Topical/Oral Antibiotics		
<input type="radio"/> UVA <input type="radio"/> UVB		
<input type="radio"/> Other		

Prescription Information

Medication	Dosage & Strength	Directions	Qty	Ref
<input type="radio"/> Humira	Pediatric Crohn's Disease <input type="radio"/> Pediatric Crohn's Starter Pack: 80mg/0.8ml, 40mg/0.4ml <input type="radio"/> Pediatric Crohn's Starter Pack: 80mg/0.8ml <input type="radio"/> 20mg/0.2ml Prefilled Syringe <input type="radio"/> 40mg/0.4ml Pen <input type="radio"/> 40mg/0.4ml Prefilled Syringe	Induction Dose: <input type="radio"/> 37 lbs to <88 lbs: Inject one 80mg pen SC on day 1, then one 40mg pen SC on day 15 <input type="radio"/> >88 lbs: Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="radio"/> >88 lbs: Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15	2	0
		Maintenance Dose: <input type="radio"/> 37 lbs to <88 lbs: Inject 20mg SC every other week <input type="radio"/> >88 lbs: Inject 40mg SC every other week	3	0
			2	
<input type="radio"/> Stelara	Pediatric Plaque Psoriasis <input type="radio"/> 45mg/0.5ml Prefilled Syringe <input type="radio"/> 45mg/0.5ml Single-Dose Vial <input type="radio"/> 90mg/ml Prefilled Syringe	Induction Dose: <input type="radio"/> <60kg: Inject 0.75mg/kg SC at week 0 <input type="radio"/> 60-100kg: Inject 45mg SC at week 0 <input type="radio"/> >100kg: Inject 90mg SC at week 0	1	0
		Maintenance: <input type="radio"/> <60kg: Inject 0.75mg/kg at week 4, then every 12 weeks thereafter <input type="radio"/> 60-100kg: Inject 45mg SC at week 4, then every 12 weeks thereafter <input type="radio"/> >100kg: Inject 90mg SC at week 4, then every 12 weeks thereafter	1	0
				0
<input type="radio"/> Taltz	Pediatric Plaque Psoriasis <input type="radio"/> 80mg/ml Single-Dose Prefilled Autoinjector <input type="radio"/> 80mg/ml Single-Dose Prefilled Syringe <i>20mg and 40mg doses for patients weighing <=50kg (110lb) must be prepared and administered by a qualified healthcare professional.</i>	Induction Dose: <input type="radio"/> >50kg: Inject 160mg SC (two 80mg injections) at week 0 <input type="radio"/> 25 to 50kg: Inject 80mg SC at week 0 <input type="radio"/> <25kg: Inject 40mg SC at week 0	2	0
		Maintenance: <input type="radio"/> >50kg: Inject 80mg SC at week 4 and every 4 weeks thereafter <input type="radio"/> 25-50kg: Inject 40mg SC at week 4 and every 4 weeks thereafter <input type="radio"/> <25kg: Inject 20mg SC at week 4 and every 4 weeks thereafter	1	

Prescriber Signature (I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs)
 Signature: _____ Signature: _____ Date: _____
Substitution Permitted **Dispense as Written**
 Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Patient Information: Name: _____ DOB: _____ Gender: M F
 Address: _____ City: _____ State: _____ Zip: _____ Phone: _____ Alt. Phone: _____
 Email: _____ Ht: _____ Wt: _____ Care Giver: _____ Allergies: No Known See Attached Charts
Prescriber Information: Name: _____ Address: _____ City: _____
 State: _____ Zip: _____ NPI: _____ Phone: _____ Fax: _____ Office Contact: _____

Statement of Medical Necessity (Please Attach All Medical Documentation)

Date of Diagnosis: _____ **ICD-10:** _____ **Other:** _____ **TB Test:** Positive Negative Date: _____
LFT: ALT: _____ AST: _____ Date: _____ **Assessment:** Moderate Mod to Severe Severe _____ % BSA Affected
 Scalp Face Chest Arms Hands Nails Back Groin Buttocks Legs Other _____ **ISGA or EASI** _____

Patient also taking methotrexate? Yes No
Serious or active infection present? Yes No
Hep B ruled out or treatment started? Yes No
Does patient have latex allergy? Yes No
Injection Training: Pharmacist to Provide Training
 Patient Trained in MD Office
 Manufacturer Nurse Support
 To Be Administered By a HCP
Product Delivery: Patient's Home
 Physician's Office Pharmacy to Coordinate

Prior Failed Treatments	Drug Name	Length of Treatment
<input type="radio"/> 5-ASA		
<input type="radio"/> Biologics		
<input type="radio"/> Corticosteroids		
<input type="radio"/> Immunosuppressants		
<input type="radio"/> Methotrexate		
<input type="radio"/> NSAIDS		
<input type="radio"/> Surgery		
<input type="radio"/> Topical/Oral Antibiotics		
<input type="radio"/> UVA OUVB		
<input type="radio"/> Other		

Prescription Information

Medication	Dosage & Strength	Direction	Qty	Ref
<input type="radio"/> Dupixent	Pediatric Atopic Dermatitis <input type="radio"/> 300mg/2ml Prefilled Syringe <input type="radio"/> 200mg/1.14ml Prefilled Syringe <input type="radio"/> 300mg/2ml Prefilled Pen <i>(only for 12 years and older)</i>	Induction Dose: <input type="radio"/> ≥ 60 kg: Inject 600mg SC (two 300mg injections) <input type="radio"/> 30 to <60 kg: Inject 400mg SC (two 200mg injections) <input type="radio"/> 15 to <30 kg: Inject 600mg SC (two 300mg injections) Maintenance Dose: <input type="radio"/> ≥ 60 kg: Inject 300mg SC every other week <input type="radio"/> 30 to <60 kg: Inject 200mg SC every other week <input type="radio"/> 15 to <30 kg: Inject 300mg SC every 4 weeks	2	0
<input type="radio"/> Humira	Hidradenitis Suppurativa <input type="radio"/> Adolescent Hidradenitis Suppurativa 80mg/0.8ml and 40mg/0.4ml Starter Pack <input type="radio"/> Adolescent Hidradenitis Suppurativa 40mg/0.4ml Starter Package <input type="radio"/> Hidradenitis Suppurativa 80mg/0.8ml Starter pack <input type="radio"/> Hidradenitis Suppurativa 40mg/0.4ml Starter pack <input type="radio"/> 40mg/0.4ml Pen <input type="radio"/> 40mg/0.4ml Prefilled Syringe	Induction Dose: <input type="radio"/> Adolescents 12 years and older 66 lbs to <132 lbs: Inject 80mg SC on day 1, then 40mg SC on day 8 and every other week thereafter <input type="radio"/> Adolescents 12 years and older >132 lbs: Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="radio"/> Adolescents 12 years and older >132 lbs: Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15 Maintenance Dose: <input type="radio"/> Adolescents 12 years and older 66 lbs to <132 lbs: Inject 40mg every other week <input type="radio"/> Adolescents 12 years and older >132 lbs: Inject 40mg on day 29 then inject 40mg every week	3 4 3 6	0 0 0 0
<input type="radio"/> Humira	Juvenile Idiopathic Arthritis + Pediatric Uveitis <input type="radio"/> 10mg/0.1ml Prefilled Syringe <input type="radio"/> 20mg/0.2ml Prefilled Syringe <input type="radio"/> 40mg/0.4ml Pen <input type="radio"/> 40mg/0.4ml Prefilled Syringe	<input type="radio"/> 22 lbs to <33 lbs: Inject 10mg SC every other week <input type="radio"/> 33 lbs to <66 lbs: Inject 20mg SC every other week <input type="radio"/> ≥66 lbs: Inject 40mg SC every other week	2	
<input type="radio"/> _____	<input type="radio"/> _____	<input type="radio"/> _____		

Prescriber Signature (I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs)
 Signature: _____ Signature: _____ Date: _____
Substitution Permitted **Dispense as Written**
 Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.